The overall goal of this project is to maintain the high containment research resources (infrastructure and facilities) required to conduct research that will facilitate the next generation therapeutics, diagnostics and vaccines for infectious diseases. The Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB) is a part of the NIAID Biodefense Facilities Network and provides maximum containment research facilities for NIAID funded investigators and other researchers, as appropriate. Additionally, the GNL is prepared and available to provide facilities and support to first line responders in the event of a public health emergency. To achieve this goal, the GNL maintains six cores focused on supporting maximum containment research facilities: 1) Administrative Core; 2) Facility Operations and Maintenance Core; 3) Biosecurity Core; 4) Environmental Health and Biosafety Regulations and Requirements Core; 5) Regulatory Requirements Core; and 6) Veterinary Support and Preclinical Services Core.

Public Health Relevance

National Biocontainment Laboratories Operational Support ensures the availability of maximum containment laboratories for research that will develop the next generation of therapeutics, diagnostics and vaccines for infectious diseases that can pose a public health risk. It also ensures that high containment labs are available in the event of a public health or bioterrorism emergency. This support is essential due to the high cost of building and maintaining laboratories that protect researchers, ensure the biosecurity of dangerous pathogens, and safeguard the communities where these laboratories are located.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
2UC7AI094660-06
Application #
9076094
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Cross, Robert W; Mire, Chad E; Agans, Krystle N et al. (2018) Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J Infect Dis 218:S448-S452
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest 127:4437-4448
Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149
Warfield, Kelly L; Warren, Travis K; Qiu, Xiangguo et al. (2017) Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Res 138:22-31
Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374

Showing the most recent 10 out of 59 publications